机译:未经治疗的侵袭性套细胞淋巴瘤患者接受利妥昔单抗-HyperCVAD联合利妥昔单抗-高剂量甲氨蝶呤/阿糖胞苷(R-MA)的强烈化学免疫治疗后且未进行干细胞移植的十年随访
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
Hackensack University Medical Center, Hackensack, NJ;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX|The Rey Juan Carlos Cancer Center, Auxilio Mutuo Hospital, San Juan;
The Hematology-Oncology Section, University of Puerto Rico, San Juan, PR, USA;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
From the Department of Lymphoma/Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX;
mantle cell lymphoma; rituximab; hyper-CVAD; methotrexate-cytarabine; survival;
机译:未经治疗的侵袭性套细胞淋巴瘤患者接受利妥昔单抗-HyperCVAD联合利妥昔单抗-高剂量甲氨蝶呤/阿糖胞苷(R-MA)的强烈化学免疫治疗后且未进行干细胞移植的十年随访。
机译:用Rituximab-Hypercvad与Rituximab-High剂量甲氨蝶呤/溶剂(R-MA)交替,并且没有干细胞移植,在未经治疗的侵袭性裂缝细胞淋巴瘤患者中进行了十年后随访。
机译:用Rituximab-Hypercvad与Rituximab-High剂量甲氨蝶呤/溶剂(R-MA)交替,并且没有干细胞移植,在未经治疗的侵袭性裂缝细胞淋巴瘤患者中进行了十年后随访。
机译:高剂量化疗加干细胞移植对转移细胞肿瘤的一线化疗失败的患者的标准治疗吗?
机译:与进行自体外周血干细胞移植的淋巴瘤患者疲劳相关。
机译:对于有套细胞淋巴瘤的患者使用利妥昔单抗-hyperCVAD与利妥昔单抗-甲氨蝶呤-阿糖胞苷交替进行一线治疗然后与90Y-伊比特单抗-替沙坦合并。 GELTAMO集团的多中心2期试验性试验的结果
机译:用Rituximab-Hypercvad与Rituximab-High剂量甲氨蝶呤/溶剂(R-MA)交替的增强化疗疗法后的十年随访,并且在未经处理的侵袭性搭腔细胞淋巴瘤患者中没有干细胞移植